Veradermics Advances Oral Hair-Loss Drug Toward 2026 Data Readouts

Veradermics is progressing its late-stage oral hair-loss candidate, VDPHL01, toward pivotal clinical data readouts scheduled for late 2026 and early 2027. The company aims to establish the drug as a first-in-class non-hormonal treatment for pattern hair loss, differing from current standard-of-care therapies.

"The announcement of positive Phase 2/3 topline results from Study '302' in April 2026 was an inflection point for Veradermics and supports our belief that VDPHL01 can become a foundational treatment for pattern hair loss," said Reid Waldman, CEO and co-founder of Veradermics, in a statement.

Clinical Development Timeline

The company is overseeing clinical trials to evaluate the efficacy and safety of the drug. Pivotal data readouts for male studies, designated as Study 304 and Study 302 Part B, are expected in the second half of 2026. Data for the female study, Study 306, is anticipated in the first half of 2027.

VDPHL01 is an investigational, extended-release oral minoxidil tablet. According to company SEC filings, the formulation is designed to maintain steady drug levels to support hair growth while potentially mitigating the cardiac risks associated with immediate-release oral minoxidil formulations.

Financial Position and Market Context

Veradermics maintains a balance sheet to support these late-stage trials. As of March 31, 2026, the company reported $390.8 million in cash, cash equivalents, and marketable securities. Since that reporting date, the company has increased its liquidity through follow-on offerings, which generated an additional $472.0 million in gross proceeds.

As of September 11, 2026, Veradermics shares were trading at $100.37. The company is focused on navigating the transition from Phase 2/3 results to the final pivotal milestones required for potential regulatory submission.

Why This Matters for Pattern Hair Loss

Most current oral treatments for androgenetic alopecia, or pattern hair loss, rely on hormonal modulation, which can carry side-effect profiles. By utilizing an extended-release mechanism for a non-hormonal agent, Veradermics is attempting to capture a segment of the market that seeks systemic efficacy without the systemic hormonal impact. The upcoming data readouts will determine if the drug maintains its clinical momentum through the final stages of the regulatory process.